Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 17/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 11/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17691164 | 0.91 | ADORA2B (0.44) | ADORA2BADORA2AADORA3ADORA1 | |
| SCHEMBL6049598 | 0.91 | ADORA2B (0.44) | ADORA2BADORA2AADORA3ADORA1 | |
| SCHEMBL6555002 | 0.90 | ADORA2B (0.42) | ADORA2BADORA2AADORA3ADORA1 | |
| SCHEMBL6049688 | 0.88 | ADORA2B (0.45) | ADORA2BADORA2AADORA3ADORA1 | |
| SCHEMBL6049561 | 0.87 | ADORA2B (0.41) | ADORA2BADORA2AADORA3ADORA1 | |
| SCHEMBL6555320 | 0.86 | ADORA2B (0.44) | ADORA2BADORA2AADORA3ADORA1 | |
| SCHEMBL6049644 | 0.86 | ADORA2B (0.47) | ADORA2BADORA2AADORA3ADORA1 | |
| SCHEMBL6049595 | 0.86 | ADORA2B (0.52) | ADORA2BADORA2AADORA3ADORA1 | |
| SCHEMBL6049659 | 0.85 | ADORA2B (0.43) | ADORA2BADORA2AADORA3ADORA1 | |
| SCHEMBL6049716 | 0.85 | ADORA2B (0.52) | ADORA2BADORA2AADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1372661-B1 | GLYCOL DERIVATVES OF XANTHINES FOR TREATING IRRITABLE BOWEL SYNDROME | SMITHKLINE BEECHAM CORP (US) | 2006-05-17 | — | — | EP | claimed |
| US-6770267-B2 | Methods of treating periodontal disease | SMITHKLINE BEECHAM CORPORATION | 2004-08-03 | — | — | US | claimed |
| US-20040072848-A1 | Methods of treating irritable bowel syndrome and functional dyspepsia | SMITHKLINE BEECHAM CORPORATION | 2004-04-15 | — | — | US | claimed |
| US-20040034020-A1 | Methods of treating periodontal disease | DALUGE SUSAN MARY (US) | 2004-02-19 | — | — | US | claimed |
| EP-1104422-B1 | PHENYL XANTHINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2004-02-18 | — | — | EP | claimed |
| US-6608069-B1 | Treating AIDS-related diarrhea or infectious diarrhea, tissue damage or dermatitis associated with leukocyte infiltration into tissue, asthma, inflammatory bowel condition, eczema, or psoriasis | SMITHKLINE BEECHAM CORPORATION | 2003-08-19 | — | — | US | claimed |
| US-20030032804-A1 | Methods of treating periodontal disease | SMITHKLINE BEECHAM CORPORATION | 2003-02-13 | — | — | US | claimed |
| EP-1104422-A1 | PHENYL XANTHINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2001-06-06 | — | — | EP | claimed |
| WO-2000009507-A1 | PHENYL YANTHINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2000-02-24 | — | — | WO | claimed |
| EP-1372661-B1 | GLYCOL DERIVATVES OF XANTHINES FOR TREATING IRRITABLE BOWEL SYNDROME | SMITHKLINE BEECHAM CORP (US) | 2006-05-17 | — | — | EP | disclosed |
| US-6770267-B2 | Methods of treating periodontal disease | SMITHKLINE BEECHAM CORPORATION | 2004-08-03 | — | — | US | disclosed |
| US-20040072848-A1 | Methods of treating irritable bowel syndrome and functional dyspepsia | SMITHKLINE BEECHAM CORPORATION | 2004-04-15 | — | — | US | disclosed |
| US-20040034020-A1 | Methods of treating periodontal disease | DALUGE SUSAN MARY (US) | 2004-02-19 | — | — | US | disclosed |
| EP-1104422-B1 | PHENYL XANTHINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2004-02-18 | — | — | EP | disclosed |
| US-6608069-B1 | Treating AIDS-related diarrhea or infectious diarrhea, tissue damage or dermatitis associated with leukocyte infiltration into tissue, asthma, inflammatory bowel condition, eczema, or psoriasis | SMITHKLINE BEECHAM CORPORATION | 2003-08-19 | — | — | US | disclosed |
| US-20030032804-A1 | Methods of treating periodontal disease | SMITHKLINE BEECHAM CORPORATION | 2003-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034020-A1 | Methods of treating periodontal disease | MMP8, LPO, PTGES3 | ADORA2B 680/4885ADORA2A 660/4885ADORA3 730/4885 |
| US-20040072848-A1 | Methods of treating irritable bowel syndrome and functional dyspepsia | SI, XDH, SLC10A2 | ADORA2B 247/4885ADORA2A 175/4885ADORA3 164/4885 |
| US-20030032804-A1 | Methods of treating periodontal disease | HPGDS, SELP, ALPI | ADORA2B 439/4885ADORA2A 300/4885ADORA3 656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.